2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. ADC Antibody

ADC antibodies act as the navigation system of ADC drugs and are primarily responsible for delivering payloads to target cells.

ADC Antibody Related Products (119):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P9907
    Trastuzumab
    		99.80%
    Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer. (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
    Trastuzumab
  • HY-P99045
    Sacituzumab
    		99.9%
    Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer.
    Sacituzumab
  • HY-P9915
    Daratumumab
    		99.10%
    Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.
    Daratumumab
  • HY-P99843
    Datopotamab
    		99.92%
    Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer.
    Datopotamab
  • HY-P9907A
    Trastuzumab (anti-HER2)
    		99.838%
    Trastuzumab (anti-HER2) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (anti-HER2) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
    Trastuzumab (anti-HER2)
  • HY-P992146
    Zevontabart
    Zevontabart (MYTX-011 Antibody; Q-397) is a pH-dependent anti-c-MET antibody. Zevontabart regulates the trafficking process of c-MET to reduce receptor recycling, and enhances its own endocytosis and accumulation in c-MET-expressing cells. Zevontabart induces cytotoxicity in solid tumor cells and exerts anti-tumor activity in a non-small cell lung cancer xenograft mouse model. Zevontabart can be used to synthesize ADC, such as: MYTX-011. Zevontabart can be used in studies related to non-small cell lung cancer, with its corresponding isotype control being Human IgG1 kappa, Isotype Control (HY-P99001).
    Zevontabart
  • HY-P992449
    REGN2878
    REGN2878 (PRLR ADC antibody) is a monoclonal antibody targeting the prolactin receptor (PRLR) and can block prolactin‑mediated activation of PRLR. REGN2878 exhibits an equilibrium dissociation constant (KD) of 1.05 nM and an IC50 of 0.344 nM for human PRLR. REGN2878 can be rapidly internalized and degraded in lysosomes by PRLR‑positive tumor cells, showing antigen‑specific binding and targeted enrichment properties. REGN2878 derivatives can be used as an immunoPET agent for antigen‑specific imaging of PRLR‑related tumors, and can also serve as a component of ADCs to exert anti‑tumor activity in breast cancer xenograft models. REGN2878 can be used in the research of breast cancer and prostate cancer. Isotype Comparison HY-P99001.
    REGN2878
  • HY-P992316
    ATG-022 Antibody
    ATG-022 Antibody is a humanized monoclonal antibody targeting Claudin 18.2 (CLDN 18.2). ATG-022 Antibody binds with VcMMAE (HY-15575) to form an Antibody-Drug Conjugate (ADC). ATG-022 Antibody can be used for the research of advanced/metastatic solid tumors and gastric cancer.
    ATG-022 Antibody
  • HY-P99225
    Mirvetuximab
    		99.88%
    Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research.
    Mirvetuximab
  • HY-P99016
    Enfortumab
    		99.90%
    Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma.
    Enfortumab
  • HY-P9980
    Belantamab
    		99.90%
    Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma.
    Belantamab
  • HY-P990673
    Vandortuzumab
    		99.00%
    Vandortuzumab (DSTP-3086S Antibody; RG-7450 Antibody) is a humanized anti-STEAP1 IgG1 antibody and antimitotic agent that can be conjugated with MMAE (HY-15162) to form the antibody-drug conjugate (ADC) Vandortuzumab vedotin. Vandortuzumab vedotin specifically binds to STEAP1 and drives internalization of the complex, releasing the MMAE (HY-15162) payload intracellularly. After binding to tubulin, MMAE inhibits cell division and induces cell death. Vandortuzumab exhibits antitumor activity in preclinical xenograft models of prostate cancer and can be used for research related to metastatic castration-resistant prostate cancer (mCRPC).
    Vandortuzumab
  • HY-P99113
    Inebilizumab
    		99.00%
    Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research.
    Inebilizumab
  • HY-P99971
    Gemtuzumab
    		99.54%
    Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Gemtuzumab
  • HY-P99054
    Tusamitamab
    		99.81%
    Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize ADC Tusamitamab ravtansine (SAR408701) (HY-P99542).
    Tusamitamab
  • HY-P99042
    Polatuzumab
    		99.69%
    Polatuzumab is a monoclonal antibody that targets CD79b on the surface of B cells. Polatuzumab can be used to synthesize the ADC Polatuzumab Vedotin (HY-132253), which has anti-tumor activity.
    Polatuzumab
  • HY-P99151
    Brentuximab
    		99.64%
    Brentuximab (CAC-10) is a chimeric antibody targeting CD30. Brentuximab is conjugated with Monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107A). Brentuximab can be used for the research of cancer, such as lymphoma.
    Brentuximab
  • HY-P99271
    Tisotumab
    		99.5%
    Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab can be used for the research of solid tumors.
    Tisotumab
  • HY-P99205
    Glembatumumab
    		99.69%
    Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity.
    Glembatumumab
  • HY-P99264
    Inotuzumab
    Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Inotuzumab